Andrea Kasinski is developing cancer drugs based on microRNAs (IMAGE)
Caption
Purdue University researcher Andrea Kasinski is leading work on the relationship between microRNAs — small, non-coding segments of RNA — and cancer, including developing a modified microRNA that curbs at least three genes known to drive cancer and therapy resistance. MicroRNAs can block multiple molecular paths that cancer cells use to grow and spread, a substantial advantage over the most advanced medicines available. Kasinski is developing the modified microRNA she designed in the lab and through LigamiR Therapeutics (a company she founded to advance RNA therapeutics) to target for triple-negative breast cancer, ovarian cancer, and non-small cell lung cancer.
Credit
Purdue University photo/John Underwood
Usage Restrictions
No restriction
License
Original content